Emerging therapeutic agents for advanced non-small cell lung cancer

Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances in targeted therapy and immunotherapy have changed the landscape for the treatment of advanced NSCLC. In the last 10 years, the US Food and Drug Administration (FDA) has approved more than 17 new medications for this devastating disease and more are coming. Molecular and immunogenic testing makes personalized medicine possible for patients with advanced NSCLC. The new medications provide promising efficacy and safety resulting in improved long-term survival for a significant number of patients. In this review, we summarize the recent advances in advanced/metastatic NSCLC therapeutics with a specific focus on first in-human or early-phase I/II clinical trials. These drugs either offer better alternatives to current standard drugs in the same class or are a completely new class of drugs with novel mechanisms of action. Advances are divided into (1) targeted agents, (2) antibody-drug conjugates, and (3) immunotherapies. Finally, we present a brief review of the emerging agents and ongoing clinical studies.

• Publication year

  2020

• Venue

  Journal of Hematology & Oncology

• Publication date

  2020-05-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s13045-020-00881-7PMID 32448366PMCID 7245927
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.

  2020cited by this paper
• Cancer statistics, 2020

  2020cited by this paper
• Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

  2020cited by this paper
• Siglec-15: An Attractive Immunotherapy Target.

  2019cited by this paper
• OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC

  2019cited by this paper
• OA02.05 First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC

  2019cited by this paper
• Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

  2019cited by this paper
• The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.

  2019cited by this paper
• Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

  2019cited by this paper
• Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

  2019cited by this paper
• Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

  2019cited by this paper
• A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.

  2019cited by this paper
• Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.

  2019cited by this paper
• Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.

  2019cited by this paper
• Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy as first-line treatment for lung cancer in Chinese patients.

  2019cited by this paper
• Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).

  2019cited by this paper
• Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

  2019cited by this paper
• A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.

  2019cited by this paper
• JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

  2019cited by this paper
• Phase II study of tepotinib in NSCLC patients with METex14 mutations.

  2019cited by this paper
• Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.

  2019cited by this paper
• A multicenter, phase II study of soluble LAG-3 (Eftilagimod alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).

  2019cited by this paper
• Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).

  2019cited by this paper
• Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.

  2019influential reference
• Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC).

  2019cited by this paper
• Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from a phase I dose escalation and NSCLC expansion cohort.

  2019cited by this paper
• Abstract 942: The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: Association with clinical outcomes

  2019cited by this paper
• Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)

  2019cited by this paper
• HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

  2019cited by this paper
• Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

  2019cited by this paper
• Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

  2019cited by this paper
• Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.

  2019cited by this paper
• Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild‐type EGFR and ALK.

  2019cited by this paper
• Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.

  2019cited by this paper
• A phase I study to evaluate safety, tolerability, pharmacokinetics and antineoplastic activity of BPI-7711 in patients with EGFR/T790M mutation advanced or recurrent NSCLC.

  2019cited by this paper
• Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

  2019cited by this paper
• A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

  2019cited by this paper
• A phase I/Ib study of crenolanib with ramucirumab (RAM)/paclitaxel (PTX) as second-line therapy (2L tx) for advanced esophagogastric adenocarcinoma (EGA).

  2019cited by this paper
• Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

  2019cited by this paper
• Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001.

  2019cited by this paper
• AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

  2019cited by this paper
• An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer.

  2019cited by this paper
• Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

  2019cited by this paper
• Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

  2019cited by this paper
• A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Drug Conjugate) given intravenously in patients with advanced solid tumours.

  2018cited by this paper
• Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer.

  2018cited by this paper
• Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

  2018cited by this paper
• Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.

  2018cited by this paper
• A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).

  2018cited by this paper
• Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).

  2018cited by this paper
• Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

  2018cited by this paper
• Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

  2018cited by this paper
• ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

  2018cited by this paper
• Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

  2018cited by this paper
• FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

  2018cited by this paper
• Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC

  2018cited by this paper
• Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

  2018cited by this paper
• A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.

  2018cited by this paper
• A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.

  2018cited by this paper
• Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.

  2018cited by this paper
• TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo

  2018cited by this paper
• Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.

  2018cited by this paper
• Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.

  2018cited by this paper
• A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.

  2018cited by this paper
• eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.

  2018cited by this paper
• OA05.02 Epacadostat Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer: Phase 1/2 Results from ECHO-202/KEYNOTE-037

  2018cited by this paper
• Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer.

  2018cited by this paper
• Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).

  2018cited by this paper
• A trial of CV301 in combination with anti-PD-1 therapy versus anti-PD-1 therapy in subjects with non-small cell lung cancer.

  2018cited by this paper
• Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).

  2018cited by this paper
• PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.

  2018cited by this paper
• Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.

  2018cited by this paper
• Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.

  2018cited by this paper
• First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.

  2018cited by this paper
• First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).

  2018influential reference
• Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.

  2018cited by this paper
• Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.

  2018influential reference
• Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.

  2018cited by this paper
• A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer.

  2018cited by this paper
• P1.01-62 The Third Generation Irreversible EGFR Inhibitor HS-10296 in Advanced Non-Small Cell Lung Cancer Patients

  2018cited by this paper
• Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.

  2018cited by this paper
• ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC

  2018cited by this paper
• First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US.

  2018cited by this paper
• NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.

  2018cited by this paper
• An open-label, phase 1b study of NEO-PV-01 with pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous non-small cell lung cancer.

  2018cited by this paper
• OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6

  2018cited by this paper
• P1.04-32 Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC

  2018cited by this paper
• Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.

  2018cited by this paper
• A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC.

  2018cited by this paper
• PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.

  2018cited by this paper
• A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

  2018cited by this paper
• Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.

  2018cited by this paper
• SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.

  2018cited by this paper
• Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

  2018cited by this paper
• Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer

  2018cited by this paper
• Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001.

  2018cited by this paper
• Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.

  2018cited by this paper
• First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.

  2018cited by this paper
• HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

  2017cited by this paper
• P2.04-013 ElevatION:NSCLC-101 – A Phase 1b Study of PDR001 Combined with Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients

  2017cited by this paper

• OSBPL2-mediated lipid metabolism alteration governs lung cancer stem cells properties.

  2026cites this paper
• Real-world outcomes of pembrolizumab-chemotherapy combination in metastatic non-small cell lung cancer by age and sex: A national population-based study.

  2026cites this paper
• Real-World Outcomes of Pembrolizumab Monotherapy in Metastatic Non-Small Cell Lung Cancer by Age and Sex: A National Population-Based Study in Australia.

  2026cites this paper
• Artificial Intelligence-Driven Clinical Decision Support Systems for Precision Oncology: A Comprehensive Review

  2026cites this paper
• Network pharmacology and experimental validation to explore the effects and mechanisms of flavonoids luteolin and chrysoeriol against non‑small cell lung cancer.

  2026cites this paper
• Patritumab deruxtecan induces immunogenic cell death

  2025cites this paper
• Comprehensive analysis of KRT18 as a novel prognostic biomarker and potential target in lung adenocarcinoma

  2025cites this paper
• Retrospective analysis of pembrolizumab-related adverse reactions and death outcomes based on the FAERS database

  2025cites this paper
• Multisequence MRI-driven assessment of PD-L1 expression in non-small cell lung cancer: a pilot study

  2025cites this paper
• First-line atezolizumab monotherapy vs. single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation.

  2025cites this paper
• Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data.

  2025cites this paper
• Aucubin inhibits the activity of lung cancer stem-like cells by targeting degradation of β-catenin.

  2025cites this paper
• Integrating genomic and pathological characteristics to enhance prognostic precision in advanced NSCLC

  2025cites this paper
• Development and characterisation of improved unifocal primary mouse lung cancer models with metastatic potential

  2025cites this paper
• Identification of immune characteristics of two lung adenocarcinoma subtypes based on immune- and pyroptosis-related genes to improve immunotherapy.

  2025cites this paper
• Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): significance in diagnosis and treatment in Asian patients

  2025cites this paper
• Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial

  2025cites this paper
• Targeted drug conjugates and molecular mechanisms in overcoming lung cancer drug resistance

  2025cites this paper
• A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer

  2025cites this paper
• Automated recognition and segmentation of lung cancer cytological images based on deep learning

  2025cites this paper
• Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance.

  2025cites this paper
• Risk factors of bone metastasis in lung adenocarcinoma

  2025cites this paper
• Mechanistic insights into Circ-MBOAT2-mediated regulation of TLK1 through miR-664b-3p in non-small cell lung cancer

  2025cites this paper
• A multi-level exploration of the genetic basis between lung cancer and schizophrenia

  2025cites this paper
• Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer

  2025cites this paper
• Neutrophil-Mediated Delivery Platforms for Synergistic Chemo-Immunotherapy of Non-Small-Cell Lung Cancer Therapy.

  2025cites this paper
• A bioinformatics exploration of lung adenocarcinoma identifies hub genes with prognostic significance: from data to discovery

  2025cites this paper
• Datopotamab deruxtecan induces hallmarks of immunogenic cell death

  2025cites this paper
• Setting the Benchmark: Patterns of Care and Outcomes for Early‐stage Non‐small Cell Lung Cancer in Queensland, Australia, 2011–2017

  2025cites this paper
• Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK)

  2025cites this paper
• Effects of Low-Dose Atorvastatin on Hypoxic Response in Statin-Sensitive and Statin-Resistant Cancer Cells.

  2025cites this paper
• Mechanistic insights into molecular targeted therapy and immunotherapy for lung cancer.

  2025cites this paper
• Imaging patterns and recommendations for diagnosis, staging, and management of lung cancer

  2025cites this paper
• Longitudinal investigation of sleep and circadian rest-activity rhythms in non-small cell lung cancer patients during immunotherapy and associations with fatigue, depression, and perceived stress.

  2025cites this paper
• CRTC1 enhances PD-L1-mediated tumor immunosuppression in non-small cell lung cancer via the Notch1/Akt signaling pathway

  2025cites this paper
• EGFR Mutation Detection in Whole Slide Images of Non‐Small Cell Lung Cancers Using a Two‐Stage Deep Transfer Learning Approach

  2025cites this paper
• Surface-modified organic nanoparticles for lung cancer targeted therapy.

  2025cites this paper
• Application value of oral targeted drug management program led by specialist nurses in continuous nursing for lung cancer patients

  2025cites this paper
• Manganese in health and disease.

  2025cites this paper
• Decline in Circadian Robustness in Lung Cancer Patients During Immunotherapy is Associated With Increased Risk of Disease Progression and Death

  2025cites this paper
• Adopting tomorrow’s therapies today: a perspective review of adoptive cell therapy in lung cancer

  2025cites this paper
• Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP)

  2025cites this paper
• Prevalence of Molecular Mutations in Non–Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion

  2025cites this paper
• Smoking cessation is a protective factor for lung cancer onset and mortality: a population-based prospective cohort study

  2025cites this paper
• Tubeimoside II potentiates anti-PD-1 therapy in NSCLC by increasing ferroptosis sensitivity and remodeling immune landscape.

  2025cites this paper
• EGFR-TKIs with or without stereotactic body radiotherapy to primary lesion in the advanced EGFR-mutated non-small cell lung cancer

  2025cites this paper
• Traitement des épistaxis de patients atteints de la maladie de Rendu-Osler avec un spray intranasal de bevacizumab (EROSB) : recherche de la dose efficace

  2025cites this paper
• Association of systemic therapy with survival among adults with advanced non-small cell lung cancer

  2025cites this paper
• Unlocking the therapeutic potential of antibody–drug conjugates in targeting molecular biomarkers in non-small cell lung cancer

  2025cites this paper
• Effects of circulating RNAs on tumor metabolism in lung cancer (Review)

  2025cites this paper
• A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer.

  2025cites this paper
• New advances of natural products in non-small cell lung cancer: from mechanisms to therapies.

  2025cites this paper
• Deep Clustering-Based Metabolic Stratification of Non-Small Cell Lung Cancer Patients Through Integration of Somatic Mutation Profile and Network Propagation Algorithm

  2025cites this paper
• Cryoablation Combined with Programmed Cell Death Protein 1 Inhibitor Pembrolizumab for Advanced Non-Small Cell Lung Cancer

  2025cites this paper
• An Enhanced Residual Architecture for Automated Detection of Bone Metastasis on Whole-Body SPECT Images

  2025cites this paper
• Updated progression of honokiol in lung cancer treatment.

  2025cites this paper
• Efficacy and safety of taletrectinib for treatment of ROS1 positive non-small cell lung cancer: A systematic review

  2025influential citation
• Neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer with driver mutations: a retrospective analysis

  2025cites this paper
• Interplay of GPC3, Hsa-miR-135b-3p, and FTLP3 in lung cancer metastasis

  2025cites this paper
• Propensity score analysis of high-dose rate brachytherapy, immune checkpoint inhibitors, and docetaxel in second-line advanced NSCLC treatment

  2025cites this paper
• Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China

  2025cites this paper
• Economic Evaluation of Penpulimab Plus Paclitaxel and Carboplatin Combination Therapy as First-Line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer in China

  2025cites this paper
• Anti-tumor role and molecular mechanism of vanillic acid

  2025cites this paper
• Heme oxygenase 1 (HO-1) is a drug target for reversing cisplatin resistance in non-small cell lung cancer

  2025cites this paper
• Investigating the determinants of fear of cancer recurrence in patients with early‐stage non‐small cell lung cancer: Insights from a restricted cubic spline model

  2024cites this paper
• A single-center, retrospective study-spring-evaluating the efficacy and safety of recombinant human vascular endothelial inhibitor combined with anti-PD-1 in elderly patients aged 80 and above with NSCLC

  2024cites this paper
• Asiaticoside Inhibits Growth and Metastasis in Non‐Small Cell Lung Cancer by Disrupting EMT via Wnt/β‐Catenin Pathway

  2024cites this paper
• 1G6‐D7 Inhibits Homologous Recombination Repair by Targeting Extracellular HSP90α to Promote Apoptosis in Non–Small Cell Lung Cancer

  2024cites this paper
• The prognostic impact of severe grade immune checkpoint inhibitor related pneumonitis in non-small cell lung cancer patients

  2024cites this paper
• Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers

  2024cites this paper
• Vismodegib Potentiates Marine Antimicrobial Peptide Tilapia Piscidin 4-Induced Cytotoxicity in Human Non-Small Cell Lung Cancer Cells

  2024influential citation
• Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and societal perspectives

  2024cites this paper
• Revealing prognostic insights of programmed cell death (PCD)-associated genes in advanced non-small cell lung cancer

  2024cites this paper
• Advances in systemic immune inflammatory indices in non-small cell lung cancer: A review

  2024cites this paper
• Neurotrophin-3 Facilitates Stemness Properties and Associates with Poor Survival in Lung Cancer

  2024cites this paper
• Evaluation of cytotoxicity and apoptotic effects of Catharanthus roseus on the human lung cancer cell lines CaLu-6

  2024cites this paper
• Ferulic Acid—A Brief Review of Its Extraction, Bioavailability and Biological Activity

  2024cites this paper
• New naphthalene-linked pyrazoline–thiazole hybrids as prominent antilung and antibreast cancer inhibitors

  2024cites this paper
• Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC

  2024cites this paper
• Lung cancer organoid-based drug evaluation models and new drug development application trends

  2024cites this paper
• Identification and interaction mechanism of novel small molecule antagonists targeting CC chemokine receptor 1/3/5 for treatment of non-small cell lung cancer

  2024cites this paper
• KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype

  2024cites this paper
• From Images to Genes: Radiogenomics Based on Artificial Intelligence to Achieve Non‐Invasive Precision Medicine in Cancer Patients

  2024cites this paper
• A comprehensive nomogram for assessing the prognosis of non-small cell lung cancer patients receiving immunotherapy: a prospective cohort study in China

  2024cites this paper
• Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

  2024cites this paper
• RGS20 promotes non-small cell lung carcinoma proliferation via autophagy activation and inhibition of the PKA-Hippo signaling pathway

  2024cites this paper
• Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study

  2024cites this paper
• Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer

  2024cites this paper
• Clinical efficacies of different neoadjuvant therapies for non-small cell lung cancer

  2024cites this paper
• Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors

  2024cites this paper
• Advances in lymphatic metastasis of non-small cell lung cancer

  2024cites this paper
• Prospects and challenges of immunotherapy for thyroid cancer.

  2024cites this paper
• A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases

  2024cites this paper
• Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer

  2024cites this paper
• Gli1-mediated tumor cell-derived bFGF promotes tumor angiogenesis and pericyte coverage in non-small cell lung cancer

  2024cites this paper
• Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice

  2024cites this paper
• Pericytes Modulate Third‐Generation Tyrosine Kinase Inhibitor Sensitivity in EGFR‐Mutated Lung Cancer Cells Through IL32‐β5‐Integrin Paracrine Signaling

  2024cites this paper
• Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy

  2024influential citation
• Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits.

  2024cites this paper
• Fibroblast Growth Factor Receptor 1-Specific Dehydrogelation to Release Its Inhibitor for Enhanced Lung Tumor Therapy.

  2024cites this paper